Review article · 2026 · Open access

The evolving landscape of pharmacogenomics: Current achievements and future directions

Volker Martin Lauschke, Magnus Ingelman‐Sundberg

Pharmacological Reviews, 78(2), 100122 · Published 2 February 2026 · DOI 10.1016/j.pharmr.2026.100122

Open full textCite this paper

In brief

“The evolving landscape of pharmacogenomics: Current achievements and future directions” is a 2026 review article by Volker Martin Lauschke and Magnus Ingelman‐Sundberg, published in Pharmacological Reviews. OpenAlex counts 16 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmacological Reviews.

Citations
16
Most cited in
2026 (16)
Field-weighted impact
14.68
References
313
Authors
2

Abstract

Pharmacogenomics investigates how inherited and acquired genetic variation shapes drug efficacy, toxicity, and treatment failure. The major therapeutic areas for pharmacogenomics-assisted drug therapy include oncology, cardiology, psychiatry, neurology, infectious diseases, pain management, and metabolic disorders. Next-generation sequencing has revealed the extensive landscape of pharmacogenetic polymorphisms at the population scale. As a result, the field has evolved from early single-gene pharmacogenetics to genome-wide approaches that encompass the entirety of pharmacogenetic variability. However, much of the heritable variation in drug response remains unexplained, reflecting rare and structural variants, complex haplotypes, and the importance of polymorphisms in factors that regulate pharmacogenes in trans. A recently emphasized factor is the importance of considering differences in substrate specificities between enzymes and transporters that carry amino acid changes. Allele frequencies of actionable genetic variants are often low, requiring large, well powered studies that carefully account for key confounders, including patient adherence, placebo effects, comorbidities, hepatic and renal dysfunction, inflammation, and drug-drug and food-drug interactions. At the same time, emerging in silico variant-effect predictors, deep mutational scanning, population biobanks, and organotypic 3-dimensional human tissue models provide scalable platforms for functionally annotating variants and modeling human drug disposition and toxicity. A major effort moving forward is the continued identification and accurate classification of clinically important drug-gene pairs, along with improved implementation of pharmacogenomics in clinical practice. Artificial intelligence can accelerate this process by enabling rapid genome interpretation, prioritizing clinically relevant variants, and translating complex data into actionable recommendations. It can also integrate pharmacogenomic findings with other omics and help mitigate bias, thereby improving equity in treatment outcomes. In conclusion, the field will continue to expand, but its success will require large, rigorously designed ancestrally diverse trials, harmonized international regulatory standards, robust cost-effectiveness evidence, and the seamless integration of artificial intelligence-supported pharmacogenomic decision tools into global clinical practice. SIGNIFICANCE STATEMENT: Pharmacogenomics is a rapidly evolving field. Here, we review its foundational background, the most important clinical applications, and future perspectives with respect to methodological advances, the role of artificial intelligence, and its translation into clinical practice.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lauschke, V. M., & Ingelman‐Sundberg, M. (2026). The evolving landscape of pharmacogenomics: Current achievements and future directions. Pharmacological Reviews, 78(2), 100122. https://doi.org/10.1016/j.pharmr.2026.100122

MLA 9

Lauschke, Volker Martin, and Magnus Ingelman‐Sundberg. “The evolving landscape of pharmacogenomics: Current achievements and future directions.” Pharmacological Reviews, vol. 78, no. 2, 2026, p. 100122. https://doi.org/10.1016/j.pharmr.2026.100122.

Chicago

Lauschke, Volker Martin and Magnus Ingelman‐Sundberg. 2026. “The evolving landscape of pharmacogenomics: Current achievements and future directions.” Pharmacological Reviews 78 (2): 100122. https://doi.org/10.1016/j.pharmr.2026.100122.

Harvard

Lauschke, V. M. and Ingelman‐Sundberg, M. (2026) ‘The evolving landscape of pharmacogenomics: Current achievements and future directions’, Pharmacological Reviews, 78(2), p. 100122. doi:10.1016/j.pharmr.2026.100122.

IEEE

V. M. Lauschke and M. Ingelman‐Sundberg, “The evolving landscape of pharmacogenomics: Current achievements and future directions,” Pharmacological Reviews, vol. 78, no. 2, p. 100122, 2026, doi: 10.1016/j.pharmr.2026.100122.

BibTeX

@article{lauschke2026evolving,
  title     = {{The evolving landscape of pharmacogenomics: Current achievements and future directions}},
  author    = {Lauschke, Volker Martin and Ingelman‐Sundberg, Magnus},
  journal   = {Pharmacological Reviews},
  year      = {2026},
  volume    = {78},
  number    = {2},
  pages     = {100122},
  doi       = {10.1016/j.pharmr.2026.100122},
  url       = {https://doi.org/10.1016/j.pharmr.2026.100122}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • drug response variability
  • drug toxicity
  • structural variants
  • haplotypes
  • variant effect prediction
  • deep mutational scanning
  • population biobanks

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Lauschke, V. M., & Ingelman‐Sundberg, M. (2026). The evolving landscape of pharmacogenomics: Current achievements and future directions. Pharmacological Reviews, 78(2), 100122. https://doi.org/10.1016/j.pharmr.2026.100122

How many times has this paper been cited?

16 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pharmacological Reviews: sign in and open the full text from this page.

Who wrote this paper?

Volker Martin Lauschke, Magnus Ingelman‐Sundberg.

What is the DOI of this paper?

10.1016/j.pharmr.2026.100122, permanently at https://doi.org/10.1016/j.pharmr.2026.100122. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.